

**SUBMITTED BY:**

**STEPHEN M. LANIER, PH.D.  
VICE PRESIDENT FOR RESEARCH**

**UNIVERSITY CONTRACT TO OPTION A TECHNOLOGY TO  
GALIMA BIOTECH, INC., A COMPANY CO-OWNED BY  
A SCHOOL OF ENGINEERING FACULTY**

**RECOMMENDATION**

The Administration recommends the Board of Governors authorize the President or his designee to contract with GALIMA BIOTECH, INC, to enter into an option for an exclusive license for commercialization of the intellectual property encompassing the Technology entitled “Compositions and Methods Relating to Galectin Detection.”

**BACKGROUND**

Juri Gelovani, M.D., professor in the Department of Biomedical Engineering at Wayne State University, along with his collaborators have developed certain technology and know-how related to PET radiotracer compounds and methods. This technology has been disclosed to the University and is described in WSU Tech ID 15-1290 and embodied in pending provisional patent application 62/197,338.

GALIMA BIOTECH Inc., was founded by Dr. Gelovani and was incorporated in Michigan on August 12, 2015. It is the intent of Galima, Inc. to further develop the technology for research and clinical applications to make them commercially viable with the long range intent to have the technology adopted by major pharmaceutical or imaging agent manufactures.

Michigan Conflict of Interest law requires specific sunshine procedures in order for a University employee, or a company owned by a University employee, to contract directly or indirectly with the University:

- (A) The employee must disclose a pecuniary interest in the contract to the Board and the disclosure must be made a matter of record in the Board’s proceedings.
- (B) The contract must be approved by a vote of not less than two-thirds of the full membership of the Board in open session.
- (C) The Board’s minutes must report:
  - (i) The name of each party involved in the contract.
  - (ii) The terms of the contract, including duration, financial consideration between parties, facilities or services of the public entity included in the contract, and the nature and degree of assignment of employees of the public entity for fulfillment of the contract.

- (iii) The nature of any pecuniary interest.

If the Board approves this Recommendation, the minutes will report as follows:

The Board of Governors authorized the President, or his designee, to contract with GALIMA BIOTECH, INC., of which Dr. Juri Gelovani holds an equity position to grant GALIMA BIOTECH, INC. an option to an exclusive license to the technology known as “Compositions and Methods Relating to Galectin Detection.”

- (i) The parties involved in the contract are Wayne State University and GALIMA BIOTECH, INC.
- (ii) The contract will provide:
  - (a) An option to acquire an exclusive, worldwide royalty bearing license.
  - (b) The option shall be for twelve (12) months.
  - (c) Financial consideration of:
    - (1) Option fee \$2,000;
    - (2) Payment of patent expense incurred during option period for preparing, filing, prosecuting and maintaining any existing or new patent applications.
  - (d) No University employees are assigned in connection with the licensing contract.

(iii) Dr. Gelovani’s pecuniary interest consists of an OWNERSHIP INTEREST, holding 100% equity in GALIMA BIOTECH and will therefore have the potential to financially benefit from the commercial success of the company, including the commercialization of the University’s Technology known as “Compositions and Methods Relating to Galectin Detection.”